Table 6.
Neoadjuvant cohort: patient and tumor characteristics (all non-black patients pooled as one group)
| Characteristic | Black N (%) | Non-Black N (%) | Total | Chi-square test (p-value) |
|---|---|---|---|---|
| All | 92 (42.99%) | 122 (57.01%) | 214 | |
| Age | 0.13 | |||
| <50 | 45 (48.91%) | 47 (38.52%) | 92 | |
| >50 | 47 (51.09%) | 75 (61.48%) | 122 | |
| Clinical stage | 0.66 | |||
| I,II | 50 (54.35%) | 70 (57.38%) | 120 | |
| III | 42 (45.65%) | 52 (42.62%) | 94 | |
| ER status | 0.0009 | |||
| Negative | 53 (57.61%) | 41 (34.75%) | 94 | |
| Positive | 39 (42.39%) | 77 (65.25%) | 116 | |
| PR status1 | 0.11 | |||
| Negative | 60 (66.67%) | 64 (55.65%) | 124 | |
| Positive | 30 (33.33%) | 51 (44.35%) | 81 | |
| HER2 status2 | 0.09 | |||
| Equivocal | 1 (1.14%) | 7 (5.98%) | 8 | |
| Negative | 71 (80.68%) | 81 (69.23%) | 152 | |
| Positive | 16 (18.18%) | 29 (24.79%) | 45 | |
| Triple-negative status3 | 0.003 | |||
| No | 46 (52.27%) | 88 (76.52%) | 134 | |
| Yes | 42 (47.73%) | 27 (23.48%) | 69 |
1
PR status missing from 9 patients: Blacks, N=90; Non-blacks, N=115.
2
HER2 status missing from 9 patients: Blacks, N=88; Non-blacks, N=117.
3
Triple-negative status missing from 11 patients: Blacks, N=88; Non-blacks, N=115.
ER = estrogen receptor; PR = progesterone receptor; HER2 = Human Epidermal Growth Factor Receptor 2